Dasatinib

Generic Name
Dasatinib
Brand Names
Sprycel
Drug Type
Small Molecule
Chemical Formula
C22H26ClN7O2S
CAS Number
302962-49-8
Unique Ingredient Identifier
X78UG0A0RN
Background

Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias. Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeric protein BCR-ABL. BCR-ABL is associated with the uncontrolled activity of the ABL tyrosine kinase and is involved in the pathogenesis of CML and 15-30% of ALL cases. Dasatinib also inhibits a spectrum of kinases involved in cancer, including several SRC-family kinases.

Unlike imatinib, another tyrosine kinase used for the treatment of CML and Ph-positive ALL, dasatinib inhibits the active and inactive conformations of the ABL kinase domain. Also, mutations in the kinase domain of BCR-ABL may lead to relapse during imatinib treatment. Since dasatinib does not interact with some of the residues involved in those mutations, the use of this drug represents a therapeutic alternative for patients with cancers that have developed imatinib-resistance. The use of dasatinib was first approved by the FDA in 2006.

Indication

Dasatinib is indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, as well as adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib, and adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. Dasatinib is also indicated for the treatment of pediatric patients 1 year of age and older with Ph+ CML in chronic phase or newly diagnosed Ph+ ALL in combination with chemotherapy.

Associated Conditions
Accelerated Phase Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukaemias (ALL), Chronic Phase Chronic Myeloid Leukemia, Blast phase Chronic myeloid leukemia
Associated Therapies
-

Dasatinib (Sprycel™) in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)

First Posted Date
2009-02-25
Last Posted Date
2016-03-01
Lead Sponsor
University of Ulm
Target Recruit Count
89
Registration Number
NCT00850382
Locations
🇦🇹

Krankenhaus der Barmherzigen Schwestern, Linz, Austria

🇦🇹

Elisabethinen Krankenhaus, Linz, Austria

🇦🇹

Universitätsklinikum Innsbruck, Innsbruck, Austria

and more 47 locations

Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)

First Posted Date
2009-01-22
Last Posted Date
2016-06-28
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
53
Registration Number
NCT00826449
Locations
🇺🇸

UT MD Anderson Cancer Center, Houston, Texas, United States

Efficacy Study of Dasatinib in Locally Advanced Triple-Negative Breast Cancer Patients

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2009-01-06
Last Posted Date
2012-08-31
Lead Sponsor
Baylor Breast Care Center
Target Recruit Count
22
Registration Number
NCT00817531
Locations
🇺🇸

Baylor College of Medicine, Lester and Sue Smith Breast Center, Houston, Texas, United States

Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia

Phase 1
Completed
Conditions
First Posted Date
2009-01-01
Last Posted Date
2012-07-17
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
5
Registration Number
NCT00816283
Locations
🇺🇸

City of Hope Medical Group, Pasadena, California, United States

🇺🇸

City of Hope Comprehensive Cancer Center, Duarte, California, United States

Phase II Study of Dasatinib in Previously Treated Patients With Advanced NSCLC

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2008-11-07
Last Posted Date
2016-06-30
Lead Sponsor
Duke University
Target Recruit Count
37
Registration Number
NCT00787267
Locations
🇺🇸

Durham VA Medical Center, Durham, North Carolina, United States

🇺🇸

Duke University Medical Center, Durham, North Carolina, United States

🇺🇸

Duke Raleigh, Raleigh, North Carolina, United States

Personalized Treatment Selection for Metastatic Breast Cancer

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2008-10-28
Last Posted Date
2020-09-03
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
97
Registration Number
NCT00780676
Locations
🇺🇸

UT MD Anderson Cancer Center, Houston, Texas, United States

A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib

Phase 2
Active, not recruiting
Conditions
Interventions
First Posted Date
2008-10-22
Last Posted Date
2023-09-13
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
130
Registration Number
NCT00777036
Locations
🇮🇹

Local Institution - 006, Monza, Italy

🇲🇽

Local Institution - 0050, Monterrey, Nuevo Leon, Mexico

🇷🇺

Local Institution - 0023, Moscow, Russian Federation

and more 106 locations
© Copyright 2024. All Rights Reserved by MedPath